Beginning Next Week: InsideCounsel will become part of Corporate Counsel. Bringing these two industry-leading websites together will now give you comprehensive coverage of the full spectrum of issues affecting today's General Counsel at companies of all sizes. You will continue to receive expert analysis on key issues including corporate litigation, labor developments, tech initiatives and intellectual property, as well as Women, Influence & Power in Law (WIPL) professional development content. Plus we'll be serving all ALM legal publications from one interconnected platform, powered by, giving you easy access to additional relevant content from other InsideCounsel sister publications.

To prevent a disruption in service, you will be automatically redirected to the new site next week. Thank you for being a valued InsideCounsel reader!


Bayer purchases Merck’s consumer care business for $14.2 billion

This deal gives Bayer control of many well-known brands, including Claritin, Coppertone, Afrin and Dr. Scholl’s

M&As seems to be all the rage for pharmaceutical companies these days. First, GlaxoSmithKline and Novartis combined forces, swapping more than $20 billion in assets to merge elements of each company’s consumer drug business. Then, Pfizer bid more than $100 billion for competitor AstraZeneca, in an attempt to become one of the world’s largest drug companies. And now, German drug maker Bayer has followed that up by purchasing a key facet of Merck’s business, becoming one of the world’s largest providers of over-the-counter products as a result.

Bayer will purchase Merck’s consumer care business for $14.2 billion, the company announced on May 6. This will give Bayer control of many well-known brands, including Claritin, Coppertone, Afrin and Dr. Scholl’s.

In addition, the two companies entered into a co-development and commercialization partnership concerning the treatment of cardiovascular diseases. Through the terms of the agreement, Merck will make an up-front payment of $1 billion to Bayer, and will continue payments of up to $1.1 billion until sales goals are hit.

“This acquisition marks a major milestone on our path towards global leadership in the attractive nonprescription medicines business,” said Bayer CEO Marijn E. Dekkers in a statement following the acquisition.

Merck, meanwhile, said that this deal allows the company to focus its efforts in key areas, such as the discovery and sale of new drugs. “The sale of our consumer care business is part of our efforts to ensure that assets within our portfolio align with our core strategy, have industry-leading potential and generate long-term shareholder value,” said Kenneth C. Frazier, Merck chairman and CEO, in a statement.

Merck’s consumer care business generated about 70 percent of its revenue in the United States, according to The New York Times. The Times also said that Morgan Stanley and the law firms Fried Frank Harris Shriver & Jacobson and Morgan, Lewis & Bockius, advised Merck on the sale.


For more on pharmaceutical companies in legal news, check out these InsideCounsel articles:

Borden leads Cooley team in Horizon Pharma’s acquisition of Vidara Therapeutics

Pfizer has its sights set on AstraZeneca for $100 billion

GlaxoSmithKline eliminates commercial ties with outside doctors following bribes

Pharma companies still fail to embrace social media  

Assistant Editor

author image

Zach Warren

Zach Warren is Assistant Editor of InsideCounsel magazine, where he oversees online content submissions and administers InsideCounsel's enewsletters. Zach specializes in new media and multimedia...

Bio and more articles

Join the Conversation

Advertisement. Closing in 15 seconds.